Q/C Technologies, Inc. Revenue from Contract with Customer, Including Assessed Tax
Q/C Technologies, Inc. (QCLS) reported Revenue from Contract with Customer, Including Assessed Tax of $302.48 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-07-13.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2018-07-13
- Q/C Technologies, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2018-03-31 was $302.48K, a 52.97% decline year-over-year.
- Q/C Technologies, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2017-03-31 was $643.19K.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month |
|---|---|
| 2018-03-31 | $302.48K 10-Q · filed 2018-07-13 |
| 2017-03-31 | $643.19K 10-Q · filed 2018-07-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |